Rowe, IA orcid.org/0000-0003-1288-0749 (2018) The devotion to surrogate outcomes in drug development for liver disease. Nature Reviews Gastroenterology and Hepatology, 15 (1). 155. ISSN 1759-5045
Abstract
Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: | |
Copyright, Publisher and Additional Information: | © 2017 Macmillan Publishers Limited, part of Springer Nature. This is an author produced version of a paper published in Nature Reviews Gastroenterology and Hepatology. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | Biomarkers, Clinical trials, Drug discovery and development, Liver diseases |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Translational Medicine (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 18 Dec 2017 16:19 |
Last Modified: | 29 May 2018 00:38 |
Status: | Published |
Publisher: | Springer Nature |
Identification Number: | 10.1038/nrgastro.2017.155 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:125329 |